Niktimvo’s approval was based on positive data from the AGAVE-201 trial, which demonstrated a 75% response rate in patients with chronic graft-versus-host disease.
FDA Approves Incyte and Syndax Pharmaceuticals’ Nictimvo for Chronic Graft-Versus-Host Disease
Leave a comment
